| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 12 | 2024 | 124 | 4.690 |
Why?
|
| Colorectal Neoplasms | 18 | 2024 | 107 | 4.040 |
Why?
|
| Circadian Rhythm | 9 | 2021 | 213 | 3.890 |
Why?
|
| Microbiota | 5 | 2024 | 65 | 2.800 |
Why?
|
| Colon | 9 | 2021 | 112 | 2.290 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 88 | 2.260 |
Why?
|
| Ethanol | 7 | 2022 | 83 | 1.980 |
Why?
|
| Metabolic Syndrome | 3 | 2023 | 55 | 1.940 |
Why?
|
| Obesity | 6 | 2023 | 288 | 1.940 |
Why?
|
| Colonic Neoplasms | 6 | 2024 | 56 | 1.670 |
Why?
|
| Inflammation | 7 | 2023 | 230 | 1.580 |
Why?
|
| Pancreas | 3 | 2023 | 30 | 1.570 |
Why?
|
| Carcinogenesis | 5 | 2019 | 20 | 1.410 |
Why?
|
| Colonic Polyps | 5 | 2019 | 29 | 1.300 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 79 | 1.290 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 82 | 1.290 |
Why?
|
| Betacoronavirus | 3 | 2020 | 69 | 1.230 |
Why?
|
| Colonoscopy | 9 | 2021 | 73 | 1.200 |
Why?
|
| Humans | 63 | 2024 | 23187 | 1.200 |
Why?
|
| Alcoholism | 4 | 2022 | 64 | 1.190 |
Why?
|
| Animals | 14 | 2022 | 3271 | 1.140 |
Why?
|
| Gastrointestinal Tract | 2 | 2018 | 41 | 1.050 |
Why?
|
| Mice | 10 | 2022 | 1240 | 0.990 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 31 | 0.920 |
Why?
|
| Alcohol Drinking | 3 | 2020 | 65 | 0.900 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 157 | 0.870 |
Why?
|
| Dysbiosis | 3 | 2023 | 36 | 0.870 |
Why?
|
| Pandemics | 3 | 2020 | 207 | 0.860 |
Why?
|
| Feeding Behavior | 4 | 2022 | 79 | 0.850 |
Why?
|
| Mutation | 4 | 2018 | 330 | 0.850 |
Why?
|
| Epithelial Cells | 3 | 2019 | 70 | 0.830 |
Why?
|
| Asthma | 3 | 2020 | 152 | 0.800 |
Why?
|
| Transcriptome | 1 | 2023 | 54 | 0.780 |
Why?
|
| Adenoma | 6 | 2021 | 59 | 0.750 |
Why?
|
| Male | 36 | 2022 | 12659 | 0.730 |
Why?
|
| Receptors, Opioid, mu | 1 | 2022 | 2 | 0.730 |
Why?
|
| Gastrointestinal Diseases | 1 | 2022 | 26 | 0.710 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 210 | 0.710 |
Why?
|
| Prebiotics | 2 | 2018 | 18 | 0.700 |
Why?
|
| Probiotics | 2 | 2018 | 15 | 0.700 |
Why?
|
| Morphine | 1 | 2022 | 70 | 0.690 |
Why?
|
| Photoperiod | 3 | 2021 | 28 | 0.690 |
Why?
|
| Time Factors | 9 | 2020 | 1264 | 0.670 |
Why?
|
| Animal Husbandry | 1 | 2020 | 6 | 0.670 |
Why?
|
| Lipase | 1 | 2020 | 4 | 0.650 |
Why?
|
| Weight Gain | 1 | 2020 | 61 | 0.640 |
Why?
|
| Intestines | 3 | 2021 | 77 | 0.630 |
Why?
|
| Eating | 1 | 2020 | 47 | 0.630 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 19 | 0.610 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2019 | 2 | 0.610 |
Why?
|
| Central Nervous System Depressants | 1 | 2019 | 14 | 0.600 |
Why?
|
| Sleep | 1 | 2021 | 270 | 0.590 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 82 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 363 | 0.580 |
Why?
|
| Insulin Resistance | 1 | 2018 | 48 | 0.560 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 15 | 0.550 |
Why?
|
| Neoplasms | 1 | 2020 | 218 | 0.550 |
Why?
|
| Macrophages | 1 | 2018 | 79 | 0.540 |
Why?
|
| Female | 31 | 2021 | 13142 | 0.540 |
Why?
|
| Intestinal Diseases | 1 | 2017 | 7 | 0.510 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 5 | 0.490 |
Why?
|
| Serpins | 1 | 2016 | 3 | 0.490 |
Why?
|
| Eye Proteins | 1 | 2016 | 6 | 0.490 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 135 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2017 | 277 | 0.470 |
Why?
|
| Nerve Growth Factors | 1 | 2016 | 33 | 0.470 |
Why?
|
| Mass Screening | 5 | 2017 | 162 | 0.470 |
Why?
|
| Interleukin-17 | 1 | 2015 | 11 | 0.460 |
Why?
|
| Middle Aged | 22 | 2024 | 7981 | 0.460 |
Why?
|
| Multiple Organ Failure | 2 | 2012 | 5 | 0.460 |
Why?
|
| Pancreatitis | 2 | 2012 | 20 | 0.450 |
Why?
|
| Diet | 3 | 2023 | 181 | 0.440 |
Why?
|
| Biopsy | 2 | 2021 | 188 | 0.440 |
Why?
|
| Risk Factors | 7 | 2022 | 2020 | 0.430 |
Why?
|
| Medicine, Arabic | 1 | 2014 | 1 | 0.430 |
Why?
|
| Adult | 23 | 2022 | 6959 | 0.430 |
Why?
|
| Hepatic Artery | 1 | 2014 | 3 | 0.420 |
Why?
|
| Infarction | 1 | 2014 | 21 | 0.420 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2014 | 22 | 0.420 |
Why?
|
| Sarcoidosis | 1 | 2014 | 13 | 0.410 |
Why?
|
| Liver Diseases | 1 | 2014 | 33 | 0.400 |
Why?
|
| Liver | 1 | 2014 | 135 | 0.380 |
Why?
|
| Feces | 3 | 2024 | 80 | 0.380 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 57 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 176 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 163 | 0.340 |
Why?
|
| Genes, ras | 2 | 2008 | 13 | 0.320 |
Why?
|
| Microsatellite Instability | 2 | 2008 | 10 | 0.320 |
Why?
|
| Aged | 18 | 2021 | 7660 | 0.320 |
Why?
|
| Biomarkers | 3 | 2020 | 486 | 0.310 |
Why?
|
| Iran | 11 | 2017 | 29 | 0.300 |
Why?
|
| Incidence | 4 | 2021 | 633 | 0.300 |
Why?
|
| Body Mass Index | 2 | 2021 | 381 | 0.290 |
Why?
|
| Food Hypersensitivity | 2 | 2020 | 40 | 0.280 |
Why?
|
| Rhinitis, Allergic | 2 | 2020 | 14 | 0.280 |
Why?
|
| Early Detection of Cancer | 4 | 2017 | 100 | 0.280 |
Why?
|
| Comorbidity | 3 | 2022 | 429 | 0.280 |
Why?
|
| Prospective Studies | 7 | 2023 | 1512 | 0.270 |
Why?
|
| Phenotype | 2 | 2021 | 260 | 0.260 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 80 | 0.260 |
Why?
|
| Sinusitis | 2 | 2020 | 152 | 0.240 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 804 | 0.230 |
Why?
|
| Esophageal Achalasia | 4 | 2006 | 17 | 0.230 |
Why?
|
| NF-kappa B | 2 | 2022 | 100 | 0.230 |
Why?
|
| Age Factors | 6 | 2020 | 651 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 778 | 0.230 |
Why?
|
| United States | 2 | 2021 | 1803 | 0.220 |
Why?
|
| Cohort Studies | 5 | 2020 | 1467 | 0.220 |
Why?
|
| Sex Factors | 4 | 2020 | 399 | 0.210 |
Why?
|
| Pilot Projects | 6 | 2023 | 369 | 0.200 |
Why?
|
| Bicycling | 1 | 2023 | 3 | 0.200 |
Why?
|
| Fibroblasts | 1 | 2023 | 50 | 0.200 |
Why?
|
| Cadherins | 2 | 2020 | 30 | 0.200 |
Why?
|
| Period Circadian Proteins | 2 | 2021 | 11 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 29 | 0.200 |
Why?
|
| Mercaptopurine | 1 | 2023 | 3 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2021 | 310 | 0.190 |
Why?
|
| beta-Glucans | 1 | 2022 | 5 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 22 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2017 | 13 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.180 |
Why?
|
| Catheterization | 4 | 2006 | 40 | 0.180 |
Why?
|
| Cell Line | 1 | 2022 | 242 | 0.170 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2021 | 5 | 0.170 |
Why?
|
| Carcinoma | 2 | 2016 | 68 | 0.170 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 1037 | 0.170 |
Why?
|
| Circadian Clocks | 1 | 2021 | 20 | 0.170 |
Why?
|
| Leptin | 1 | 2020 | 18 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 150 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 162 | 0.160 |
Why?
|
| Food | 1 | 2020 | 30 | 0.160 |
Why?
|
| Glucose | 1 | 2020 | 45 | 0.160 |
Why?
|
| Eczema | 1 | 2020 | 3 | 0.160 |
Why?
|
| Random Allocation | 1 | 2020 | 102 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 243 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 17 | 0.160 |
Why?
|
| Insulin | 1 | 2020 | 77 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2021 | 129 | 0.160 |
Why?
|
| Olfaction Disorders | 1 | 2020 | 38 | 0.160 |
Why?
|
| Blood Glucose | 1 | 2020 | 104 | 0.160 |
Why?
|
| Immunity, Mucosal | 1 | 2019 | 11 | 0.150 |
Why?
|
| Butyrates | 1 | 2019 | 12 | 0.150 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2019 | 1 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 11 | 0.150 |
Why?
|
| Colitis | 1 | 2019 | 25 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 57 | 0.150 |
Why?
|
| DNA Damage | 1 | 2019 | 25 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 1657 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2019 | 63 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2019 | 39 | 0.150 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 175 | 0.150 |
Why?
|
| Adolescent | 4 | 2020 | 1884 | 0.150 |
Why?
|
| Biodiversity | 1 | 2019 | 31 | 0.150 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2018 | 5 | 0.150 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 2 | 0.150 |
Why?
|
| Immune System | 1 | 2018 | 10 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 294 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 148 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 29 | 0.140 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 3 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 11 | 0.140 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 24 | 0.140 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 37 | 0.140 |
Why?
|
| Mice, SCID | 1 | 2018 | 39 | 0.140 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 3 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 25 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2018 | 2943 | 0.140 |
Why?
|
| Occult Blood | 1 | 2017 | 3 | 0.140 |
Why?
|
| Organoids | 1 | 2017 | 7 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2018 | 164 | 0.130 |
Why?
|
| Stem Cells | 1 | 2017 | 34 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2017 | 47 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 526 | 0.130 |
Why?
|
| Pollen | 1 | 2016 | 2 | 0.130 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Mast Cells | 1 | 2016 | 18 | 0.130 |
Why?
|
| Awareness | 1 | 2016 | 40 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 5 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 17 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 30 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 25 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 27 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 26 | 0.120 |
Why?
|
| Family | 1 | 2016 | 88 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 72 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 36 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 3865 | 0.110 |
Why?
|
| Mice, Knockout | 1 | 2016 | 276 | 0.110 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 3 | 0.110 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2015 | 5 | 0.110 |
Why?
|
| Acute Disease | 2 | 2012 | 163 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 338 | 0.110 |
Why?
|
| Developing Countries | 1 | 2014 | 13 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 22 | 0.110 |
Why?
|
| Rhinitis | 1 | 2016 | 136 | 0.110 |
Why?
|
| Global Health | 1 | 2014 | 30 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 547 | 0.110 |
Why?
|
| Abdominal Pain | 1 | 2014 | 6 | 0.100 |
Why?
|
| Cholecystitis | 1 | 2014 | 8 | 0.100 |
Why?
|
| Environment | 1 | 2014 | 37 | 0.100 |
Why?
|
| Aneurysm, False | 1 | 2014 | 6 | 0.100 |
Why?
|
| Angiography | 1 | 2014 | 25 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 60 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 53 | 0.100 |
Why?
|
| Life Style | 1 | 2014 | 167 | 0.100 |
Why?
|
| Pennsylvania | 1 | 2012 | 6 | 0.090 |
Why?
|
| Natural Language Processing | 1 | 2012 | 10 | 0.090 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 15 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2012 | 42 | 0.090 |
Why?
|
| Software | 1 | 2012 | 50 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 85 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2012 | 124 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2012 | 64 | 0.090 |
Why?
|
| Genotype | 1 | 2012 | 265 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2017 | 2993 | 0.080 |
Why?
|
| Geography | 1 | 2009 | 15 | 0.080 |
Why?
|
| Genes, p53 | 1 | 2009 | 18 | 0.080 |
Why?
|
| Food Supply | 1 | 2009 | 11 | 0.080 |
Why?
|
| CpG Islands | 1 | 2009 | 43 | 0.080 |
Why?
|
| Permeability | 2 | 2021 | 94 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2009 | 9 | 0.070 |
Why?
|
| Caco-2 Cells | 2 | 2023 | 43 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 50 | 0.070 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2006 | 6 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 85 | 0.070 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2006 | 1 | 0.060 |
Why?
|
| Botulinum Toxins | 1 | 2006 | 8 | 0.060 |
Why?
|
| Codon | 1 | 2006 | 5 | 0.060 |
Why?
|
| Italy | 1 | 2006 | 15 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 550 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 125 | 0.060 |
Why?
|
| Registries | 1 | 2005 | 174 | 0.050 |
Why?
|
| Prognosis | 2 | 2020 | 730 | 0.050 |
Why?
|
| Neuromuscular Agents | 1 | 2004 | 3 | 0.050 |
Why?
|
| Celecoxib | 1 | 2023 | 6 | 0.050 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2023 | 4 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2023 | 8 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 18 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2023 | 29 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 15 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2023 | 54 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 31 | 0.050 |
Why?
|
| Thioguanine | 1 | 2023 | 3 | 0.050 |
Why?
|
| Azathioprine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Chronotherapy | 1 | 2023 | 5 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 64 | 0.050 |
Why?
|
| Syk Kinase | 1 | 2022 | 7 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 29 | 0.050 |
Why?
|
| Meals | 1 | 2022 | 10 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2021 | 10 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 19 | 0.040 |
Why?
|
| Luciferases | 1 | 2021 | 25 | 0.040 |
Why?
|
| Apoptosis | 1 | 2022 | 194 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 83 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2022 | 387 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 13 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 30 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2019 | 23 | 0.040 |
Why?
|
| Freezing | 1 | 2019 | 11 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 39 | 0.040 |
Why?
|
| Motor Activity | 1 | 2021 | 274 | 0.040 |
Why?
|
| Bacteria | 1 | 2019 | 61 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 598 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 9 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 5 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Jejunum | 1 | 2017 | 10 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Chromogranin A | 1 | 2017 | 8 | 0.030 |
Why?
|
| Occludin | 1 | 2017 | 8 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 25 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2017 | 26 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2017 | 33 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 33 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 210 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 68 | 0.030 |
Why?
|
| Protein Splicing | 1 | 2016 | 1 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2016 | 1 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 5 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 14 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 235 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 227 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 231 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 105 | 0.030 |
Why?
|
| Injections | 2 | 2006 | 42 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 485 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 123 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 11 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 13 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 380 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 17 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 13 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 15 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 377 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 67 | 0.030 |
Why?
|
| Recurrence | 2 | 2006 | 268 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 194 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 1430 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2012 | 3 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2012 | 8 | 0.020 |
Why?
|
| Data Mining | 1 | 2012 | 4 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 29 | 0.020 |
Why?
|
| Cecum | 1 | 2012 | 10 | 0.020 |
Why?
|
| Informed Consent | 1 | 2012 | 21 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 111 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 103 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 442 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 445 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 38 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 2006 | 5 | 0.020 |
Why?
|
| Coronary Care Units | 1 | 2006 | 5 | 0.020 |
Why?
|
| Angioplasty | 1 | 2006 | 5 | 0.020 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2006 | 2 | 0.020 |
Why?
|
| Barium | 1 | 2006 | 13 | 0.020 |
Why?
|
| Manometry | 1 | 2006 | 15 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2006 | 44 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2006 | 92 | 0.020 |
Why?
|
| Chest Pain | 1 | 2006 | 20 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 30 | 0.010 |
Why?
|
| Esophagus | 1 | 2006 | 53 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 63 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2006 | 130 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 69 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 29 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 74 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 116 | 0.010 |
Why?
|
| Endoscopy | 1 | 2006 | 167 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 521 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 89 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2004 | 48 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 119 | 0.010 |
Why?
|
| Child | 1 | 2004 | 1160 | 0.010 |
Why?
|